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AbstrACt
Introduction Current evidence on epidemiology and outcomes 
of invasively mechanically ventilated intensive care unit (ICU) 
patients is predominantly gathered in resource-rich settings. 
Patient casemix and patterns of critical illnesses, and probably 
also ventilation practices are likely to be different in resource-
limited settings. We aim to investigate the epidemiological 
characteristics, ventilation practices and clinical outcomes of 
patients receiving mechanical ventilation in ICUs in Asia.
Methods and analysis PRoVENT-iMIC (study of 
PRactice of VENTilation in Middle-Income Countries) is 
an international multicentre observational study to be 
undertaken in approximately 60 ICUs in 11 Asian countries. 
Consecutive patients aged 18 years or older who are 
receiving invasive ventilation in participating ICUs during 
a predefined 28-day period are to be enrolled, with a daily 
follow-up of 7 days. The primary outcome is ventilatory 
management (including tidal volume expressed as mL/kg 
predicted body weight and positive end-expiratory pressure 
expressed as cm H2O) during the first 3 days of mechanical 
ventilation—compared between patients at no risk for 
acute respiratory distress syndrome (ARDS), patients at risk 
for ARDS and in patients with ARDS (in case the diagnosis 
of ARDS can be made on admission). Secondary outcomes 
include occurrence of pulmonary complications and all-
cause ICU mortality.
Ethics and dissemination PRoVENT-iMIC will be the first 
international study that prospectively assesses ventilation 
practices, outcomes and epidemiology of invasively 
ventilated patients in ICUs in Asia. The results of this large 
study, to be disseminated through conference presentations 
and publications in international peer-reviewed journals, 
are of ultimate importance when designing trials of invasive 
ventilation in resource-limited ICUs. Access to source data 
will be made available through national or international 
anonymised datasets on request and after agreement of the 
PRoVENT-iMIC steering committee.
trial registration number NCT03188770; Pre-results.
IntroduCtIon 
Invasive mechanical ventilation is a frequently 
applied intervention in patients in intensive 
strengths and limitations of this study
 ► PRactice of VENTilation in Middle-Income Countries 
is an international multicentre observational study 
with a wide representation of Asian countries, al-
lowing inferences on epidemiology, management 
and outcomes of mechanical ventilation across the 
entire subcontinent.
 ► The attention on ventilation practice will provide ro-
bust data on this specific domain while the 7 days 
follow-up will allow precise recording of pulmonary 
complications at their origin.
 ► The study will have a sample size large enough to 
obtain precise estimates of pulmonary complica-
tions and intensive care unit mortality and to ex-
amine potential associations between ventilation 
practice and these outcomes.
 ► One limitation is the potential constraint of laborato-
ry data, generating a limited dataset not comprising 
daily severity scores useful for statistical controlling 
purposes.
 ► The conceivable limitation in blood gas analysis and 
imaging examinations may limit the documentation 
of insurgence or worsening of acute respiratory dis-
tress syndrome and other pulmonary complications.
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care units (ICUs) and a mandatory strategy in patients 
under general anaesthesia for surgery. There is increased 
understanding how invasive ventilation can harm the 
lungs, in ICU patients with the acute respiratory distress 
syndrome (ARDS),1 as well as in ICU patients with less 
injured or uninjured lungs, and in surgery patients who 
usually have healthy lungs.2 A central cause is that invasive 
ventilation with positive pressure may overdistend one 
lung area while failing to recruit another, compromising 
gas exchange but also, and more importantly, increasing 
or inducing pulmonary injury. There is convincing 
evidence that this harm can be partly prevented by 
adjusting volume and pressure settings on the ventilator. 
Indeed, use of low tidal volumes (VT),
3–5 to prevent overd-
istension, and sufficient positive end-expiratory pressure 
(PEEP),3 5 6 to prevent alveolar collapse or atelectrauma, 
have both been found to improve outcomes of various 
types of patients, and their use is increasingly recom-
mended.7–9 Furthermore, the driving pressure seems to 
be another key variable in the development of injury 
caused by mechanical ventilation, as a large individual 
patient data meta-analysis showed a clear and consistent 
association between driving pressure and mortality.10 
Practice of invasive ventilation has evolved over time, 
with a more extensive use of ventilator settings that are 
proven to prevent against so-called ventilator-induced 
lung injury. The recent LUNG SAFE (‘Large observa-
tional study to UNderstand the Global impact of Severe 
Acute respiratory Failure’) showed that by now up to 
two in every three patients with ARDS receive so-called 
lung-protective ventilation.11 Results of PRoVENT (‘PRac-
tice of VENTilation in critically ill patients without ARDS 
at onset of ventilation study’) are in line with those from 
LUNG SAFE, showing that one in every two ICU patients 
without ARDS receive ventilation with lung-protective 
settings.12 Results of LAS VEGAS (‘Local ASsessment of 
VEntilatory Management During General Anaesthesia for 
Surgery study’) even suggests increased use of lung-pro-
tective ventilation in the operating rooms.13 It should be 
noticed, though, that LUNG SAFE, PRoVENT and LAS 
VEGAS were mainly performed in high-income coun-
tries, and exclusively recruiting patients in resource-rich 
centres, which limits the generalisability of their results 
to lower-income countries and resource-limited settings. 
Historical descriptions of cohorts of invasively ventilated 
patients in resource-poor settings have been published, 
but these were all small in size, and while suggesting the 
existence of ventilator-related deaths they largely failed 
to report key ventilator parameters.14–16 Continued use of 
high VT has been reported in a recent Brazilian study,
17 
while a study from India suggests a change towards the 
use of lower VT.
18
There are several reasons to consider important differ-
ences with regard to practice of ventilation between 
resource-rich and resource-limited settings. The disparity 
in resources may limit the availability as well as the safety 
of certain ventilator settings.19 Awareness of the impact 
of invasive ventilation on lung tissue, and the benefit 
of using lung-protective ventilation settings could be 
severely limited.20 VT and PEEP may be poorly titrated due 
to insufficient staffing, and due to the absence of arterial 
blood gas monitoring, pulse oximetry or capnography.21 
Other reasons not to implement use of low VT and suffi-
cient levels of PEEP include alleged side effects associated 
with their use, like the need for higher respiratory rates, 
increased sedation requirements and even the promotion 
of patient-ventilator asynchrony. As invasive ventilation 
with higher PEEP may cause haemodynamic instability, 
limited access to fluids and vasoactive drugs may hamper 
its use. Finally, as resource-poor ICUs are usually situated 
in tropical countries their casemix and indications for 
invasive ventilation are strikingly different.18
To gain a better insight into the ventilation practice, 
outcomes and epidemiological characteristics of ICU 
patients receiving invasive ventilation in resource-limited 
settings, we plan to perform the PRoVENT-iMIC (‘Prac-
tice of VENTilation in Middle-Income Countries study’), 
a prospective observational cohort study in ICUs in Asia. 
We also aim to describe the association between certain 
ventilator settings and patient-centred outcomes. We 
hypothesise that practice of ventilation is highly variable, 
in particular with respect to VT and PEEP settings. This 
understanding is fundamental to planning any interven-
tion study in these countries in the future.
MEthods And AnAlysIs
design and setting
PRoVENT-iMIC is an international multicentre observa-
tional study in consecutive ICU patients receiving invasive 
mechanical ventilation during a 28-day period, expected 
to run in approximately 60 centres in the following 
Asian countries: Thailand, Vietnam, Myanmar, Pakistan, 
Nepal, Bangladesh, Malaysia, Sri Lanka, Maldives, Iran 
and India. These countries belong to the low-income 
or middle-income economies, as classified by the World 
Bank.22 PRoVENT-iMIC is conducted in accordance with 
the Declaration of Helsinki and is registered at www. clini-
caltrials. gov (trial identification number NCT 03188770). 
Figure 1 shows the study flow chart.
study population
Consecutive patients intubated for ventilation during a 
predefined period of 28 days are enrolled. Inclusion is 
not restricted to patients who are intubated in the ICU, as 
also patients who started invasive ventilation in the emer-
gency room, normal ward, community or operating room 
directly preceding the present ICU admission are eligible 
for participation, without any minimum or maximum 
hours of ventilation needed for inclusion. The exclu-
sion criteria include age <18 years, use of non-invasive 
ventilation not followed by invasive ventilation, patients 
whose invasive mechanical ventilation started before the 
28-day period of inclusion, and patients transferred from 
another hospital under invasive ventilation.
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Patients will be stratified in three groups for compar-
ison of the primary and secondary endpoints: patients 
without ARDS, patients without but at risk for develop-
ment of ARDS, according to the Lung Injury Predic-
tion Score (LIPS, table 1)23 and patients with ARDS, 
according to the Berlin definition.24 Patients with ARDS 
will also be stratified according to severity of ARDS, based 
on the oxygenation (mild, moderate and severe ARDS 
categories).
study conduct
Local investigators will screen all patients who start inva-
sive ventilation in one of the participating ICUs during 
a predefined period of 28 days, lasting from 08:00 hours 
on the Monday of the first week to 07:59 hours on the 
Monday 4 weeks later. The exact starting date will be flex-
ible for participating centres and shall be determined by 
the national study coordinator. Data collection has started 
in November 2017 in some sites; all sites are expected 
to initiate the service evaluation within 1 year after the 
overall start.
data to be collected
Baseline and demographic variables will be collected on 
the day of admission, including gender, age, actual or 
estimated weight and height, smoking status, comorbid-
ities including chronic obstructive pulmonary disease, 
active cancer, heart failure, diabetes mellitus, chronic 
kidney failure, liver cirrhosis and arterial hypertension, 
the presence of ARDS according to the Berlin definition, 
the LIPS, reason for ICU admission. On the day of start 
of invasive ventilation, we will document the reason for 
starting mechanical ventilation and whether the patient 
received non-invasive ventilation before intubation.
Every day, until day 3 from admission in the ICU, 
until ICU discharge or death, whichever comes first, the 
ventilation status and ventilation characteristics will be 
collected, including ventilation mode, VT size, respira-
tory rate (set and measured), peak and plateau pressure, 
PEEP, inspired oxygen fraction, peripheral oxygen satu-
ration, blood gas analysis data when available (arterial 
oxygen tension, arterial carbon dioxide tension, arterial 
bicarbonate, arterial pH), end-tidal CO2, when avail-
able and haemodynamic parameters like heart rate and 
systolic blood pressure.
Every day, until day 7, ICU discharge or death, which-
ever comes first, the occurrence of pulmonary compli-
cations will be scored, including new requirement of 
invasive ventilation after initial extubation, pulmonary 
infections, atelectasis, pneumothorax, pleural effusions, 
new pulmonary infiltrates and development or worsening 
of ARDS.
On the day of ICU discharge (maximum 60 days after 
recruitment), outcome will be recorded as follows: death, 
discharge to ward, to medium care or high dependency 
Figure 1 Flow chart of inclusion of PRoVENT-iMIC. ARDS, 
acute respiratory distress syndrome; ICU, intensive care 
unit; LIPS, Lung Injury Prediction Score; MV, mechanical 
ventilation; PRoVENT-iMIC, PRactice of VENTilation in 
Middle-Income Countries. 
Table 1 Lung Injury Prediction Score calculation worksheet 
17 34
Predisposing 
conditions Score Risk modifiers Score
Shock 2 Alcohol abuse 1
Aspiration 2 BMI >30 kg/m2 1
Sepsis 1 Hypoalbuminaemia 1
Pneumonia 1.5 Chemotherapy 1
High-risk surgery FiO2>0.35 (>4 L/min) 2
  Orthopaedic spine 1 RR >30 bpm 1.5
  Acute abdomen 2 SpO2<95% 1
  Cardiac 2.5 Acidosis (PH <7.35) 1.5












*To consider only in patients with sepsis.
BMI, body mass index; FiO2, inspired oxygen fraction; RR, 
respiratory rate; SpO2, pulse oximetry oxygen saturation.
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unit, discharge to home for palliative care, or transfer to 
another ICU. The date of extubation, reintubation and 
tracheostomy (if performed) will also be recorded in this 
moment.
study endpoints
The primary endpoint is VT size in millilitres per kilogram 
of predicted body weight (mL/kg PBW) and PEEP in 
centimetres of water (cm H2O) used among diverse ICU 
patient categories during the first 3 days of mechanical 
ventilation. Secondary clinical endpoints include other 
ventilation parameters (including respiratory system 
driving pressure, the proportion of patients at risk of 
ARDS as stratified by the LIPS or ARDS defined by the 
Berlin definition, the occurrence of pulmonary compli-
cations, length of stay in ICU, duration of invasive ventila-
tion and all-cause ICU mortality.
definitions
All-cause ICU mortality is defined as any death in the 
ICU. ICU length of stay is defined as the time between 
ICU admission and ICU discharge or death in ICU. The 
number of days of ventilation is defined as time between 
endotracheal intubation and successful extubation (in 
case of intermittent mechanical ventilation via a tracheos-
tomy, every day a patient needs ventilation counts as one 
extra day, irrespective of the duration of ventilation on 
that specific day). In case of non-invasive ventilation, the 
duration will be assessed separated from the assessment of 
invasive ventilation. The presence of spontaneous activity 
will be identified by any recorded difference between the 
set and measured respiratory rate.
Driving pressure will be calculated by subtracting 
the level of PEEP from the plateau pressure (Pplat in 
volume-control ventilation) or maximal airway pres-
sure (Pmax in pressure-control ventilation). Pplat and 
Pmax are considered reliable for this calculation if 
the patient is receiving complete ventilatory assistance 
without evidence of spontaneous activity, that is, only 
when the set respiratory rate equals the measured respi-
ratory rate. Peak airways pressures will not be used to 
compute driving pressure as these represent a poor 
surrogate of the plateau pressure. Only pulmonary 
complications that occur after the first 24 hours of inva-
sive ventilation will be considered in analysis, as events 
preceding this time point may very well be considered 
the potential reason for intubation. A pulmonary infec-
tion requires the presence of new or changed lung 
opacities on chest radiography and/or new or changed 
sputum plus at least a temperature >38.3°C or a white 
cell count >12 x10^9/L of blood. Atelectasis require 
the presence of increased density (lung opacity) on 
one or more chest radiographs with displacement of 
the fissures towards the area of atelectasis, crowding of 
pulmonary vessels and bronchi in the atelectatic region, 
upward displacement of hemidiaphragm ipsilateral to 
the side of atelectasis, that may be accompanied by 
shift of the mediastinum or hilum towards the affected 
area and compensatory overinflation in the unaffected 
lung.25 Pleural effusion is suggested by lung opacifica-
tion with shift of the mediastinum, hilum or hemidia-
phragm towards the non-affected area. Pneumothorax 
requires the presence of air in the pleural space with 
no vascular bed surrounding the visceral pleura. ARDS 
is defined according to the Berlin definition24 with 
alternative oxygenation criteria based on pulse oxim-
etry oxygen saturation/fractional inspired oxygen 
Table 2A The Berlin definition of ARDS
Criteria Definition
Time Within 1 week of a known clinical insult or new/worsening respiratory symptoms.
Chest imaging* Bilateral opacities not fully explained by effusions, lobar/lung collapse or nodules.
Origin of oedema Respiratory failure not fully explained by cardiac failure or fluid overload; need objective assessment 
to exclude hydrostatic oedema if no risk factors present (eg, echocardiography).
Oxygenation† Mild
200<PaO2/FiO2≤300
PEEP or CPAP‡≥5 cm H2O
Moderate
100<PaO2/FiO2≤200
PEEP ≥5 cm H2O
Severe
PaO2/FiO2≤100
PEEP ≥5 cm H2O
*Chest X–ray or CT scan.
†If altitude higher than 1000 m correction factor should be made as follows: PaO2/FiO2x(barometric pressure/760).
‡This may be delivered non-invasively in the mild ARDS.
ARDS, acute respiratory distress syndrome; CPAP, continuous positive airway pressure; FiO2, fractional inspired oxygen; PaO2, arterial oxygen 
tension; PEEP, positive end-expiratory pressure.
Table 2B Alternative oxygenation criteria (if PaO2 data unavailable)
Criteria Mild ARDS Moderate ARDS Severe ARDS
Oxygenation 235<SpO2/FiO2≤315
PEEP or CPAP ≥5 cm H2O
150<SpO2/FiO2≤235
PEEP ≥5 cm H2O
SpO2/FiO2≤150
PEEP ≥5 cm H2O
ARDS, acute respiratory distress syndrome; CPAP, continuous positive airway pressure; FiO2, fractional inspired oxygen; PaO2, arterial oxygen 
tension; SpO2, pulse oximetry oxygen saturation; PEEP, positive end-expiratory pressure. 
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applicable only when blood gas analysis data is unavail-
able (table 2A,B).26 27 Worsening of ARDS is defined as 
any change in the prior classification (ie, from mild to 
moderate or severe ARDS, or from moderate to severe 
ARDS).
data management
Data will be collected from a paper medical chart, or an 
electronic patient data management system if available. 
Local investigators transcribe the collected data directly 
onto an anonymised internet-based electronic case 
report form (CRF) (Research Electronic Data Capture,28 
www. projectredcap. org). In some centres, data may be 
recorded on paper CRF and successively transcribed on 
the electronic CRF at a later time point. Access to the 
data-entry system is protected by a personalised username 
and password. The data will be kept on a central secured 
server located at the Hospital Israelita Albert Einstein, 
Sao Paulo, Brazil. The structure of the electronic CRF is 
detailed in figure 2. A screening log with limited patient 
data will be completed with all the included and excluded 
patients during the enrolment window. Participating 
centres are instructed to enter data for the daily follow-up 
using values obtained as close as possible to 08:00 hours, 
but only when the patient is stable at that time point. The 
study day for the recording of pulmonary complications 
will be defined as the natural 24 hours period from 00:00 
to 23:59 hours, to ensure that data are captured only once. 
Data for ICU discharge will be collected until a maximum 
of 60 days after ICU admission, after which the CRF for 
that patient will be closed.
study sites
PRoVENT-iMIC will be conducted in 11 Asian countries, 
with a varying number of ICUs per country. Participating 
ICUs are selected on the basis of willingness to partici-
pate. There are no a priori established requirements 
for participation, and private as well as public centres 
are eligible to represent real-life practices. A one-time 
web-based prestudy survey on structure, organisational 
aspects and delivery of care in the participating centres 
will be performed. Each participating centre is surveyed 
once regarding the following information: hospital char-
acteristics (private vs public), ICU characteristics (medical 
vs surgical vs mixed and open vs closed, number of ICU 
beds, annual number of patient admitted, number of 
ventilators available, and other organ support measures) 
and staffing (nurse-to-patient ratio, physician-to-patient 
ratio, presence of specialised medical staff and overnight 
coverage).
statistical analysis plan
No formal sample size calculation was performed, but we 
expect each centre to enrol 20–40 patients in the allo-
cated time period, yielding a total of 1200–2400 patients. 
We consider this figure sufficient to analyse the study 
endpoints.
Normally distributed variables will be expressed by 
their mean and SD; not normally distributed variables 
will be expressed by their medians and IQR; categorical 
variables will be expressed as n (%). In test groups of 
continuous normally distributed variables, Student’s t-test 
will be used. Likewise if continuous data are not normally 
Figure 2 Sequence of data submission in the electronic case report form. ARDS, acute respiratory distress syndrome; CPE, 
cardiogenic pulmonary oedema; ICU, intensive care unit; LIPS, Lung Injury Prediction Score; MV, mechanical ventilation.
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distributed, the Mann-Whitney U test will be used. Cate-
gorical variables will be compared with the χ2 test or 
Fisher’s exact test or when appropriate as relative risks. 
Statistical uncertainty will be expressed by 95% CIs.
The primary outcome (VT size (mL/kg PBW) and 
PEEP (cm H2O) levels during the first 3 days of mechan-
ical ventilation) will be analysed and compared between 
patients at no risk for ARDS, patients at risk for ARDS 
and in patients with ARDS (in case the diagnosis of ARDS 
could be made on admission). If the data are normally 
distributed, one-way analysis of variance (ANOVA) or 
two-way ANOVA assessing the time interaction between 
groups and days of observation will be used. When not 
normally distributed the Kruskal-Wallis test or Friedman 
test assessing the time interaction between groups and 
days of observation will be used.
Univariate analysis will be performed to identify poten-
tial factors associated with outcomes including, but not 
limited to, ventilator settings (in particular VT and PEEP). 
A multivariate logistic regression model will be used to 
determine which of those factors are independent. A 
stepwise approach will be used to enter new terms into 
the model, with a limit of p<0.2 to enter the terms. Time 
to event variables is analysed using Cox regression and 
visualised by Kaplan-Meier.
Time-course variables (eg, repeated measures of venti-
lator parameters, vital signs, oxygenation parameters and 
others) are also analysed by linear mixed model. The 
linear mixed-models procedure expands the generalised 
linear model so that the data are permitted to exhibit 
correlated and non-constant variability.
Prespecified subgroups in the analyses studying poten-
tial associations between ventilator settings and outcome 
will be: (1) patients at low risk of ARDS versus patients at 
risk of ARDS; (2) patients without ARDS versus patients 
with ARDS; (3) reason for ICU admission and (4) reason 
for start of invasive ventilation. Statistical analyses will be 
conducted using R (www. r- project. org). A p value of less 
than 0.05 will be considered statistically significant.
study organisation
The Steering Committee is composed of a selection of 
PROVE Network investigators plus the national coordi-
nators from each participating country. These investi-
gators were involved in the design of PRoVENT-iMIC. 
National coordinators are responsible for identifying 
and recruiting local participating centres. They assist and 
train the local investigators and oversee the conduct of 
the study, including administrative management, record 
keeping and data management. Local investigators in 
individual participating centres will provide scientific and 
structural leadership, ensuring local ethical and regula-
tory approvals are obtained before start of patient inclu-
sion. National coordinators and local investigators are 
expected to guarantee the quality and security of the data 
collected.
Prior to start of the study, study teams in each centre will 
undergo a web-based training session on how to capture 
data in the electronic CRF. All study team members will 
be provided with a manual of operations with instructions 
on how to accurately fill the forms and the screening log. 
Incomplete or incorrectly entered electronic CRFs will 
be signalled to the local investigators by the national 
and international coordinator, for further review of the 
missing or flagged data.
Patient and public involvement
Patients and public were not directly involved in any 
phase of this study.
EthICs And dIssEMInAtIon
Data management, monitoring and reporting of the study 
will be performed in accordance with the International 
Conference on Harmonisation—Good Clinical Practice 
guidelines.
All participating centres will also submit the study 
protocol to the national or local institutional review board 
for ethical judgement, as applicable by the current regula-
tions in the country. Due to the strict observational design 
and anonymous collection of data, informed consent 
may not be required in most countries. However, where 
informed consent is required, this must be approved by 
the local ethical committee before the start of inclusion.
The study will be reported following the Strengthening 
the reporting of Observational Studies in Epidemiology 
statement guidelines and checklists.29 The results of this 
study will be published in a peer-reviewed medical journal. 
After publication of the primary results, on request the 
pooled dataset will be available for all members of the 
PRoVENT-iMIC collaboration for secondary analysis, after 
judgement and approval of scientific quality and validity 
of the proposed analysis by the Steering Committee.
dIsCussIon
PRoVENT-iMIC is designed to characterise the epide-
miology, ventilator management, occurrence of pulmo-
nary complications and outcomes in invasively ventilated 
patients in an estimated 60 ICUs in 11 Asian countries. 
The results of PRoVENT-iMIC will help to understand 
current ventilation practice in South and Southeast Asia, 
particularly with respect to variability in ventilator settings 
among patients without, at risk for or with established 
ARDS. Results of this study will be used to plan future 
trials of ventilation in ICU patients in these settings.
PRoVENT-iMIC has several strengths. First, its prospec-
tive design will allow a higher accuracy of data capturing 
with regard to exposures, confounders and endpoints 
compared with studies that used a retrospective design.30 
While a prospective design may cause sources of bias 
and fail to establish causal effects, it minimises the 
chance of residual confounding by unmeasured vari-
ables, a common limitation with a retrospective design, 
as has frequently been used in mechanical ventilation 
epidemiological studies.31–33 We will have a sample size 
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large enough to obtain precise estimates of pulmonary 
complications and ICU mortality and to examine poten-
tial associations between ventilation practice and patient 
outcomes. Second, the study sample is not restricted to 
certain patient diagnostic categories. Third, the atten-
tion on ventilation practice will provide robust data on 
this specific domain while the 7 days follow-up will allow 
precise recording of pulmonary complications at their 
origin. And finally, the wide representation of Asian coun-
tries will allow inferences on geoeconomic differences in 
epidemiology, management and outcomes of mechanical 
ventilation across the entire subcontinent.
The focus on South and Southeast Asia follows our 
scarce knowledge about clinical practices and ventila-
tion strategies used in critically ill patients in this and 
other resource-limited settings.21 The burden of crit-
ical illness in low-income and middle-income countries 
is higher than generally perceived and it is expected to 
increase with an ageing population.34 Additionally, ICUs 
are increasingly being set up in the region, especially in 
busy urban settings. A recent survey highlighted consider-
able variation in structure, organisation and critical care 
delivery in Asian ICUs, but did not shed light on ventila-
tion management and patient-centred ventilation-associ-
ated outcomes.35 This information, however, is crucial for 
future trials of ventilation in ICU patients in these settings, 
as we need to know whether critically ill patients across 
Asia equally benefit from lung-protective ventilation 
as those in Western countries. Additionally, for proper 
power calculations, information with regard to potential 
primary endpoints, like the incidence of development of 
ARDS, duration of ventilation or death, is highly needed. 
PRoVENT-iMIC will be the first observational study that 
can provide this information for settings in South Asia. 
Results restricted to individual settings could also be valu-
able for local clinicians seeking to improve their local 
practice, training planning and identify local priorities 
for quality improvement within their departments.
There is now strong evidence-based support for various 
ICU process-based interventions such as lung-protective 
ventilation,36 conservative fluid management strategies37 
and weaning protocols.38 While centre-specific or coun-
try-specific practices or restrictions of resources are poten-
tial challenges that affect implementation of all these 
interventions, we focus on the management of ventila-
tion and especially on the employment of lung-protective 
ventilation where feasibility may represent an issue-spe-
cific to resource-limited settings. Recent literature has 
underlined the potential role of the driving pressure (the 
pressure amplitude during each artificial breath) and its 
determinants in the development of ventilator-associated 
lung injury. Results from PRoVENT-iMIC will provide 
further data to enable us to discriminate the effects of VT 
size, PEEP and driving pressure on outcomes in patients 
with, at risk of, or without ARDS.
PRoVENT-iMIC will provide important data regarding 
outcomes following invasive ventilation, including a wide 
range of clinically important pulmonary complications. 
Historical studies from low-resource settings documented 
mortality rates to exceed 70%.14–16 However, more recent 
data from South America and India have documented 
mortality rates of ~40%, similar to that in high-income 
countries.17 18 This suggests that mortality in ventilated 
patients has the potential to improve in low-resource 
settings.12 13 39 Although many factors may influence 
mortality, several underappreciated factors related to 
invasive ventilation may have contributed, including 
reduced need for invasive ventilation per se, improve-
ments in safety of invasive ventilation and in liberation 
from invasive ventilation.
Our interest in patients at risk of ARDS follows a 
global recent shift in ARDS research. It is now clear 
that ARDS is rarely present at the time of the initial 
healthcare encounter, and typically develops during the 
hospital course, usually between days 2 and 5 in patients 
with predisposing conditions or risk factors.40 Hence, 
increasing efforts are being directed towards early iden-
tification of patients at risk with a goal of prevention and 
early treatment prior to the development of a fully estab-
lished syndrome. This is probably equally important in 
resource-limited settings where the predisposing condi-
tions and risk modifiers for ARDS may differ and limited 
escalation of therapy is often the case. PRoVENT-iMIC 
will be the first study to evaluate prospectively the role 
of LIPS in these settings. Although the poor predictive 
accuracy of the LIPS does not currently support its use 
in everyday clinical practice,41 it has enabled enrolment 
in clinical trials of ARDS prevention23 and may yield an 
initial idea on the patients at risk of and disease progres-
sion in the Asian settings under study.
PRoVENT-iMIC has some noticeable shortcomings. 
The definition of ‘middle-income’ country is rather arti-
ficial as the level of health expenditure, local resources 
and other geocultural factors might affect the processes 
of care in a larger extent than national income classifi-
cation. Despite the inclusion of ICUs from 11 countries, 
which improves study generalisability, caution is needed 
when applying the results to supposedly similar settings, 
as substantial intranational and transnational varia-
tions in ICU resources, staffing and organisation exist. 
Second, the CRF used in PRoVENT-iMIC was designed 
so that it would not induce excessive workload for the 
participating centres. Therefore, we decided not to 
collect data regarding extrapulmonary complications 
and hospital discharge outcomes, neither the amounts 
of sedation used and sedation levels. Similarly, due to 
the time window restricted to the ICU stay, we will apply 
the LIPS at ICU admission and not in the first 6 hours 
after hospital admission, as originally designed. Mortality 
may be underestimated in some settings where due to 
local practices there is the possibility to be discharged 
home in case of terminal conditions or family decision. 
To address this we made sure the data collection form 
captures this event whenever it represents the reason of 
discharge. Third, due to the limitation of laboratory data, 
we will have a limited dataset that will not comprise daily 
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severity scores useful for statistical controlling purposes. 
Also, the conceivable limitation in blood gas analysis and 
radiology examinations may limit the documentation of 
insurgence or worsening of ARDS and other pulmonary 
complications. Fourth, as in patients on pressure-con-
trol modes flow might not reach zero during inspiration, 
Pmax might overestimate alveolar pressure, hence over-
estimating driving pressure. An end-inspiratory occlusion 
could solve this problem, but is almost never performed 
in many centres. As this study only uses data that is 
collected as part of standard care, all analysis regarding 
driving pressure will be done separately for patients on 
pressure-control modes and volume-control modes. 
Finally, we cannot exclude that ventilator settings applied 
by treating physicians might be biased by the participa-
tion in the study, a problem that also existed in prior 
multinational studies.11 12 Also participation in interna-
tional studies like PRoVENT-iMIC always bears the risk of 
biased to those centres that do not fully or reliably repre-
sent ICU care in general in the participating countries.
ConClusIons
PRoVENT-iMIC is designed to understand the epidemi-
ology, practice of ventilation and outcomes of critically 
ill patients receiving invasive ventilation in a large set of 
South Asian countries. Results of this study could help 
identify practices that may best explain differences in 
outcomes, and could be used in designing new trials of 
ventilation in these settings.
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